Lorazepam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Lorazepam: Trigeminal nerve neoplasm
One-Sentence Summary
Lorazepam is a benzodiazepine originally used for anxiety disorders and seizure conditions such as status epilepticus, absence epilepsy and Lennox-Gastaut syndrome. The TxGNN model’s top-ranked prediction is trigeminal nerve neoplasm, but no clinical trials and no publications support it, so it rests on computational prediction alone. The better-supported directions among the top 10 predictions are insomnia (16 publications, including small lorazepam studies from 1988 and 1999) and micturition-induced seizures (19 indirect publications on benzodiazepines in seizures).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Lorazepam is a benzodiazepine, and this class acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission. This explains its established use in anxiety and seizures.
For trigeminal nerve neoplasm, no plausible mechanistic link to a disease-modifying effect has been established. Lorazepam could at most serve as supportive care (for example anxiety or seizure control), which is not a treatment of the tumour itself. The very high score (0.9987) should be read as a model output, not as evidence of efficacy.
Other top-10 predictions are more coherent with the drug’s pharmacology:
- Insomnia: The sedative-hypnotic effect of GABA-A enhancement is a plausible mechanism, and benzodiazepines are used for insomnia in practice. Dependence, tolerance and next-day sedation limit long-term use, and guidelines generally favour short-term use only.
- Reflex seizure types (reading, thinking, eating, startle, micturition-induced, orgasm-induced and audiogenic seizures): These are plausible given lorazepam’s existing anticonvulsant use, but disease-specific evidence is almost entirely absent.
- Acute encephalopathy with biphasic seizures and late reduced diffusion: Lorazepam might control the seizures symptomatically, but there is no evidence it alters the underlying encephalopathy.
Clinical Trial Evidence
Currently no related clinical trials registered for trigeminal nerve neoplasm, or for any of the other nine top-ranked predicted indications.
Literature Evidence
Trigeminal nerve neoplasm (rank 1): Currently no related literature available.
For reference, the best-supported alternative predictions are shown below. Many of the retrieved papers are indirect.
Insomnia (rank 2, evidence level L3)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10220122 | 1999 | Clinical study | Int Clin Psychopharmacol | Compared lorazepam 0.5 mg three times daily with 1.5 mg at bedtime in primary chronic insomnia |
| 3280615 | 1988 | Double-blind crossover (8 patients) | J Clin Pharmacol | Lorazepam 2 mg performed better than flurazepam 30 mg on most sleep parameters over 3 weeks |
| 30625122 | 2018 | Review | Med Lett Drugs Ther | Overview of drugs for chronic insomnia |
| 36692463 | 2023 | Meta-analysis | Acta Pharm | Tranquilizer use, doses and adverse effects in elderly patients with chronic diseases |
Micturition-induced seizures (rank 7, evidence level L3, indirect)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22335736 | 2012 | RCT | N Engl J Med | Intramuscular vs intravenous benzodiazepine therapy in prehospital status epilepticus (indirect) |
| 35194860 | 2022 | Meta-analysis | Addiction | Comparative pharmacotherapies for alcohol withdrawal (indirect) |
| 35971024 | 2022 | Review | CNS Drugs | Routes of delivery, pharmacokinetics, efficacy and tolerability of benzodiazepines in seizures |
| 38358613 | 2024 | Review | CNS Drugs | Benzodiazepines as the mainstay for acute treatment of seizure clusters |
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11593256 | 2001 | Case series (5 cases) | Neurol India | Lorazepam as adjuvant therapy in photosensitive epilepsy |
| 21951369 | 2011 | Review | CNS Neurosci Ther | Acute drug administration in epilepsy |
India Market Information
There are 20 valid single-ingredient registrations. Approved indication text is not available for these licenses. The main authorizations are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 42314 | Calmese 2mg Tablet (Themis Medicare) | Strip of 10 tablets | Not available |
| 11188 | Axitan 2mg Injection (Biologic Psychotropics India) | Ampoule of 2 ml injection | Not available |
| 127576 | Loracalm 2mg Tablet (Torrent Pharmaceuticals) | Strip of 10 tablets | Not available |
| 215769 | Trapex 1mg Tablet (Sun Pharmaceutical Industries) | Strip of 10 tablets | Not available |
| 142946 | Matbenz 2 MD Tablet (Matias Healthcare) | Strip of 10 mouth-dissolving tablets | Not available |
Available forms are oral tablets (including a mouth-dissolving form) and one injectable.
Safety Considerations
- Contraindications suggested by the knowledge graph (these are graph associations, not label text): liver failure, liver disease, hepatic encephalopathy and hepatic coma; kidney disease; respiratory failure, sleep apnoea syndromes and congenital central hypoventilation syndrome; open-angle and angle-closure glaucoma; porphyria; and substance-related disorders or substance abuse/dependence.
- Drug Interactions: 265 interactions were identified. Major ones include morphine (including liposomal morphine), consistent with additive central nervous system and respiratory depression. Moderate interactions include bupropion, dronabinol, nabilone, metoclopramide, opium, sibutramine and teduglutide. Antacids such as magnesium oxide, aluminium hydroxide and calcium carbonate are minor.
- Other safety points from the literature: Dependence and withdrawal are described in preclinical studies, and propylene glycol toxicity has been reported with intravenous lorazepam infusion. Guidelines caution against benzodiazepines as initial treatment for insomnia, agitation or delirium in older adults.
Package insert warnings and contraindications for the Indian products were not available, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, trigeminal nerve neoplasm, has no trials, no literature and no plausible mechanism for treating the tumour, so it is supported only by the model score. Among the other top predictions, insomnia and the reflex seizure types are pharmacologically plausible but remain research questions. Insomnia is also a use already common in practice and limited by dependence risk.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Indian products (currently a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- Approved indication text for the Indian licenses, to confirm the baseline indications
- For insomnia: a structured review of controlled evidence on short-term lorazepam use, including dependence and next-day sedation risks
- For the seizure predictions: disease-specific case series or registry data, and a judgement on whether they add anything beyond lorazepam’s existing seizure indications
- For trigeminal nerve neoplasm: a clinical rationale, if any, before further work, since only supportive-care use appears plausible
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.